PUK21 THE PSYCHOMETRIC VALIDATION OF AN US ENGLISH SATISFACTION MEASURE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA  by Black, L et al.
Hospital do Rim from Universidade Federal de São Paulo (dialy-
sis center) where 208 patients make use of human recombinant
erythropoietin (ESA) for anemia management. Structured inter-
views with personnel were arranged to identify workﬂow for
anemia management. Time spent in each activity was registered
using a stop watch by a trained professional. Time spent in less
frequent activities or in activities were the direct relation with
anemia management could not be done were not taken into
consideration for this study. For valuing time and supplies the
dialysis center’s costs data was considered. RESULTS: Total time
spent for ESA administration by the dialysis center for the treat-
ment of 208 patients was 75 days or R$19,758. Assuming the
usage of C.E.R.A. in 100% patients of the center, the time spent
by the staff would be 10 days or R$2683, representing an 86%
reduction versus current practice. Costs of supplies needed for
the administration were R$28,863 for those patients receiving
conventional ESA and R$774 if patients would have received
C.E.R.A. As a result, potential total savings generated with the
use of C.E.R.A. was R$ 45,165 per year in this dialysis center or
R$ 217/patient/year. CONCLUSION: The study suggests that
the adoption of once-monthly C.E.R.A. can bring substantial
savings for the dialysis center: R$44,847 per year or R$216 per
patient per year. Once-monthly C.E.R.A. could also improve
resource utilization and enable health care staff to focus more
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OBJECTIVE: To compare the health-related quality of life
(HRQOL) between patients undergoing continuous ambulatory
peritoneal dialysis (CAPD), automated peritoneal dialysis (APD)
and haemodialysis (HD) in the “IMSS” (Mexican Institute of
Social Security) in Guadalajara. METHODS: Transverse analytic
study included 131 patients, in peritoneal dialysis, 18 years,
any gender, or time under dialysis. Patients with acute technique-
related complications, in terminal phase of illness, or with physi-
cal or mental disability were excluded. An interview, clinical
history and detailed physical examination were carried out.
Using the Kidney Disease Quality of Life Short Form (KDQOL-
SFTM), we measured HRQOL.Analysis of variance was used
to examine differences. RESULTS: Patients were studied (50
undergoing CAPD, 34 APD and 47 HD). The average age was
46.2  18.3 years, 53% were females, and 49% were males.
The time in CAPD was 23.4  17.2, APD 23.9  14.2 and
HD 37  34 months. Physical functioning (37  28), pain
(69  25), emotional well-being (52  26), social function
(57  30), and energy/fatigue (37  27) were signiﬁcantly lower
scores in CAPD in comparison with APD (65  31, 93  12,
75  28, 91  15, 60  28) and HD (57  29, 82  17,
69  23, 80  21, 53  28). The Effects of Kidney Disease
(86  15) and Burden of Kidney Disease (58  36) subscales
were lower in APD in comparison with CAPD (76  16 and
24  29, respectively); no differences between CAPD and HD.
The physical component summary was signiﬁcantly higher in
APD (58  22) in comparison with CAPD (46  15) and HD
(34  15). Mental component summary was less in CAPD
(36  15) in comparison with APD (60  22) and HD
(46  15). CONCLUSION: The HRQL in patients undergoing
CAPD was less in comparison with patients with APD and HD.
The physical dimension was higher in patients with APD in
comparison with CAPD and HD, whereas the mental dimension
was less in the CAPD group. There was no signiﬁcant difference
between the APD and HD groups.
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OBJECTIVE: Subjects with overactive bladder (OAB) have
decreased health-related quality of life (HRQL). The positive
effects of fesoterodine (FESO) and tolterodine extended release
(TER) have been established in subjects with OAB using patient-
reported outcomes. This analysis assessed the effects of FESO
and TER on individual items of the King’s Health Questionnaire
(KHQ). METHODS: This is a post hoc analysis of data from a
multicenter, double-blind, placebo (PBO)–controlled trial. Eli-
gible subjects with frequency and urgency or urgency urinary
incontinence were randomized to PBO, FESO 4 mg, FESO 8 mg,
or TER 4 mg for 12 weeks. Subjects completed the KHQ at
baseline and end of treatment. The KHQ includes 9 domains
with 21 items and a Symptom Severity scale; lower scores indi-
cate better HRQL. Analysis of covariance was used to assess
treatment-related effects on the 21 individual items of the 9 KHQ
domains, with treatment and region as factors and baseline value
as a covariate. RESULTS: By the end of the study, FESO 8 mg
signiﬁcantly improved responses to 13 items vs. PBO; in com-
parison, FESO 4 mg and TER improved responses to 9 and 8
items, respectively (all P < 0.01). There were no signiﬁcant dif-
ferences between treatment groups. Seven items did not improve
with any treatment; most of these items were part of the Personal
Relationships and General Health Perception domains. In
general, items that improved the most with treatment had higher
baseline values (ie, worse HRQL) compared with those that did
not improve. CONCLUSION: Both doses of FESO (4 and 8 mg)
signiﬁcantly improved HRQL in subjects with OAB as evidenced
by signiﬁcantly better scores for 9 and 13 items of the KHQ vs
PBO, respectively. The domains showing improvement were
those for which improvement with OAB treatment would be
expected.
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OBJECTIVE: Measuring the treatment effectiveness from the
patients’ perspectives is recommended in managing benign pro-
static hyperplasia (BPH). The purpose of this study was to vali-
date the US English Patient Perception of Study Medication
Questionnaire (PPSMQ) administered to BPH patients in a
randomized clinical trial. METHODS: Patients with moderate-
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to-severe BPH completed three disease-speciﬁc instruments at
baseline and at follow-up visits: the International Prostate
Symptom Score (IPSS, a 7-item urinary symptom severity scale),
the BPH Impact Index (BII, a 4-item well-being scale associated
with BPH) and the PPSMQ (a 12-item instrument measuring
patient satisfaction in control of urinary symptoms, strength of
urinary stream, pain of urination and effect on usual activities
due to the pharmacotherapy). The psychometric performance,
including reliability, validity and responsiveness, of the PPSMQ
was analyzed. RESULTS: The mean age of the study sample was
66.7 years (n = 879). The PPSMQ demonstrated good internal
consistency (Cronbach’s alpha = 0.88 to 0.96) and reliability
(intraclass coefﬁcient = 0.37 to 0.40). Convergent validity of the
PPSMQ subscale and total scores measured by the Pearson coef-
ﬁcient ranged from 0.48 to 0.58 for the IPSS and 0.31 to 0.45 for
the BII, suggesting correlations between the PPSMQ and another
two logically-related instruments. The PPSMQ also demon-
strated discriminant validity against the IPSS, IPSS QoL item and
BII (F = 52.5, 42.3, and 26.9, respectively, p-values < 0.001). The
PPSMQ detected treatment differences between the monotherapy
and combination therapy arms: total scores at baseline for the
combination therapy, dutasteride and tamsulosin treatment
groups were 25.6, 25.8, and 25.7 (higher scores indicating lower
satisfaction), respectively; at two years, the scores were 17.8,
20.3, and 20.4, respectively. CONCLUSION: The PPSMQ dem-
onstrated good reliability, validity and responsiveness in measur-
ing patient satisfaction with the pharmacology treatments
for BPH. The PPSMQ may be an important addition to the
existing outcome measures used to assess BPH symptoms and
their treatments.
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OBJECTIVE: Although various instruments have been used to
assess the prevalence of LUTS, the interpretability of questions
from a patient perspective has not been assessed. There is a
need for qualitative research to inform the development of a
patient reported outcome (PRO) tool that assesses all LUTS.
METHODS: A series of eight focus groups and 66 cognitive
debrieﬁng interviews were conducted to elicit patient descrip-
tions of urinary symptoms and to assess treatment-seeking
behavior and treatment outcomes. Participants with a range of
LUTS were recruited from urology clinics and community set-
tings in different USA geographic regions. Trained interviewers
conducted each session following semi-structured interview
guides. Content and descriptive analyses were performed.
RESULTS: A total of 129 people (66 men, 63 women) partici-
pated. Mean age was 54 (26–80 y); 71% were white. Mean
symptom duration was 7 years for men; 15 years for women. A
wide range of LUTS were reported with participants generally
understanding and agreeing on the words used to describe most
LUTS. There were no differences in terminology used by clinical
and community participants. Some difﬁculty describing bladder
area pain, split stream, terminal dribble and post-micturition
dribble was noted. Most participants identiﬁed with the word
“bother” and thought it was important to assess both the fre-
quency and bother of each symptom. Reasons for seeking care
included symptom bother and fears about cancer and bladder
infections. When asked to describe a positive treatment outcome,
64% of participants responded that a 50% improvement in at
least one LUTS would be meaningful. A draft LUTS tool was
developed based on patient feedback. CONCLUSION: There is a
need for a new PRO tool to assess the frequency and bother of all
LUTS in terms understood by patients. A new LUTS PRO tool
was developed to include the patient perspective and is undergo-
ing validation.
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OBJECTIVE: Nocturia Quality of Life (N-QOL) questionnaire is
a self-administered, nocturia-speciﬁc, QoL instrument developed
to examine QoL impact of nocturia in male patients. This study
was designed to evaluate content and face validity of the N-QOL
in female patients. METHODS: Twenty women (mean age 59
years; range 27–83) diagnosed with nocturia (2 voids/night)
were recruited through U.S. urology clinics. To establish content
and face validity, the items and response options in the question-
naire must be considered relevant and comprehensive. The
N-QOL questionnaire was evaluated using 2 methodologies.
First, 15 patients provided information on their experiences of
the impact of nocturia on their QoL and reported the most
bothersome consequences of nocturia in a focus group format.
Patient responses were thereafter compared with N-QOL items
to evaluate how well they reﬂected the N-QOL concepts being
measured. Second, ﬁve patients directly evaluated the N-QOL in
an interview format using standardized cognitive debrieﬁng
methodology. RESULTS: Of the 20 participants (80% Cauca-
sian, 10% African-American, 10% Hispanic), 45% had their
condition for more than 5 years (45% had 3 voids/night and
25% 4 voids/night). Seventy percent had nocturia secondary to
OAB, and 30% were currently taking prescription medication
for the underlying cause of their nocturia. Disrupted sleep was
the most bothersome consequence of nocturia, which resulted
in sleeping longer into the daytime hours, being too tired to
exercise, eating at night, weight gain, difﬁculty concentrating,
and reduced productivity during daytime. This corresponded
well with N-QOL concepts. Directly evaluated the N-QOL was
found simple, clear, easy to complete, and comprehensive.
CONCLUSION: The N-QOL has face and content validity in
female nocturia patients, with sleep disruption causing severe
impact on daytime activities, as the most bothersome conse-
quence. The N-QOL items and response options are relevant and
comprehensive for assessing the impact of nocturia on QoL of
female patients.
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